MétaCan
Menu
Back to cohort
Record W4200171022 · doi:10.1111/jop.13270

Efficacy and safety of a novel mucoadhesive clobetasol patch for treatment of erosive oral lichen planus: A phase 2 randomized clinical trial

2021· article· en· W4200171022 on OpenAlex
Michael T. Brennan, Lars Siim Madsen, Deborah Saunders, Joel J. Napeñas, Christine McCreary, Richeal Ní Ríordáin, Anne Marie Lynge Pedersen, Stefano Fedele, Richard J. Cook, Rafik Abdelsayed, Maria T. Llopiz, Vidya Sankar, Kevin M. Ryan, Donna A. Culton, Yousra Akhlef, Fausto Castillo, Inti Fernandez, Sabine Jurge, Alexander Ross Kerr, Chad M. McDuffie, Tim McGaw, Alan J. Mighell, Thomas P. Sollecito, Thomas Schlieve, M Carrozzo, Athena Papas, Thomas Bengtsson, Ibtisam Al‐Hashimi, Laurie B. Burke, Nancy W. Burkhart, Shauna Culshaw, Bhavik Desai, J. Mølholm Hansen, Pia Jensen, Torkil Menné, Paras Patel, Martin H. Thornhill, Nathaniel S. Treister, Thomas Ruzicka

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.
aboutThe title or abstract carries a Canadian signal from the geographic lexicon.

Bibliographic record

VenueJournal of Oral Pathology and Medicine · 2021
Typearticle
Languageen
FieldDentistry
TopicOral Health Pathology and Treatment
Canadian institutionsAlberta Hospital EdmontonNOSM UniversityNortheast Cancer CentreHealth Sciences North
FundersUniversity College London Hospitals NHS Foundation TrustNational Institute for Health and Care ResearchInnovationsfonden
KeywordsDermatologyMedicineOral lichen planusRandomized controlled trialSurgery

Abstract

fetched live from OpenAlex

Abstract Background Oral lichen planus (OLP) is a chronic inflammatory disorder of the oral mucosa. Currently there is no approved treatment for OLP. We report on the efficacy and safety of a novel mucoadhesive clobetasol patch (Rivelin ® ‐CLO) for the treatment of OLP. Methods Patients with confirmed OLP and measurable symptomatic ulcer(s) participated in a randomized, double‐blind, placebo‐controlled, multicenter clinical trial testing a novel mucoadhesive clobetasol patch (Rivelin ® ‐CLO) in OLP across Europe, Canada, and the United States. Patients were randomized to placebo (nonmedicated), 1, 5, 20 µg Clobetasol/patch, twice daily, for 4 weeks. The primary endpoint was change in total ulcer area compared to baseline. Secondary endpoints included improvement from baseline in pain, disease activity, and quality of life. Results Data were analyzed and expressed as mean [SD]. One hundred thirty‐eight patients were included in the study; 99 females and 39 males, mean age was 61.1 [11.6] years. Statistical analyses revealed that treatment with 20‐μg Rivelin ® ‐CLO patches demonstrated significant improvement with ulcer area ( p = 0.047), symptom severity ( p = 0.001), disease activity ( p = 0.022), pain ( p = 0.012), and quality of life ( p = 0.003) as compared with placebo. Improvement in OLP symptoms from beginning to the end of the study was reported as very much better (best rating) in the 20‐µg group (25/32) patients compared to the placebo group (11/30), ( p = 0.012). Adverse events were mild/moderate. Candidiasis incidence was low (2%). Conclusions Rivelin ® ‐CLO patches were superior to placebo demonstrating statistically significant, clinically relevant efficacy in objective and subjective improvement and, with a favorable safety profile.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.031
Threshold uncertainty score0.584

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0030.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.134
GPT teacher head0.475
Teacher spread0.342 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it